Logo do repositório
 
Publicação

Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease

dc.contributor.authorDoglio, Matteo
dc.contributor.authorCrossland, Rachel E.
dc.contributor.authorAlho, Ana Cristina
dc.contributor.authorPenack, Olaf
dc.contributor.authorDickinson, Anne M.
dc.contributor.authorStary, Georg
dc.contributor.authorLacerda, João
dc.contributor.authorEissner, Günther
dc.contributor.authorInngjerdingen, Marit
dc.date.accessioned2023-02-07T12:24:00Z
dc.date.available2023-02-07T12:24:00Z
dc.date.issued2022
dc.descriptionCopyright © 2022 Doglio, Crossland, Alho, Penack, Dickinson, Stary, Lacerda, Eissner and Inngjerdingen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractHematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, among which chronic graft-versus-host disease (cGVHD) can be life-threatening. A classical therapeutic approach to the prevention and treatment of cGVHD has been broad immunosuppression, but more recently adjuvant immunotherapies have been tested. This review summarizes and discusses immunomodulatory approaches with T cells, including chimeric antigen receptor (CAR) and regulatory T cells, with natural killer (NK) cells and innate lymphoid cells (ILCs), and finally with mesenchymal stromal cells (MSC) and extracellular vesicles thereof. Clinical studies and pre-clinical research results are presented likewise.pt_PT
dc.description.sponsorshipThis work was supported by COST (European Cooperation in Science and Technology). www.cost.eu - COST Action 17138 EUROGRAFT.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Immunol. 2022 Nov 17;13:1045168pt_PT
dc.identifier.doi10.3389/fimmu.2022.1045168pt_PT
dc.identifier.eissn1664-3224
dc.identifier.urihttp://hdl.handle.net/10451/56198
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/immunologypt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCARpt_PT
dc.subjectILCspt_PT
dc.subjectMSCspt_PT
dc.subjectNK cellspt_PT
dc.subjectTregspt_PT
dc.subjectChronic GVHDpt_PT
dc.subjectExtracellular vesiclespt_PT
dc.titleCell-based therapy in prophylaxis and treatment of chronic graft-versus-host diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Immunologypt_PT
oaire.citation.volume13pt_PT
person.familyNameAlho
person.familyNameLacerda
person.givenNameAna Cristina
person.givenNameJoão
person.identifier690449
person.identifier559297
person.identifier.ciencia-id7F1F-164E-9201
person.identifier.ciencia-id6412-2B63-2364
person.identifier.orcid0000-0001-8803-3453
person.identifier.orcid0000-0003-1351-2809
person.identifier.scopus-author-id57117470800
person.identifier.scopus-author-id6603819609
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7d54b7cc-ae62-4806-98da-556f4731f221
relation.isAuthorOfPublicationafb302b1-8272-48de-b347-cb5b54a0a3da
relation.isAuthorOfPublication.latestForDiscovery7d54b7cc-ae62-4806-98da-556f4731f221

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Cell_therapy.pdf
Tamanho:
3.59 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição: